Revance Therapeutics (NASDAQ:RVNC) Raised to “Hold” at StockNews.com

StockNews.com upgraded shares of Revance Therapeutics (NASDAQ:RVNCGet Rating) from a sell rating to a hold rating in a research note published on Monday morning.

A number of other brokerages also recently issued reports on RVNC. Guggenheim boosted their price target on Revance Therapeutics to $35.00 in a report on Monday, August 15th. Barclays boosted their price objective on Revance Therapeutics from $22.00 to $35.00 and gave the company an overweight rating in a research report on Friday, September 9th. HC Wainwright boosted their price target on Revance Therapeutics from $25.00 to $29.00 and gave the stock a buy rating in a research report on Friday, September 9th. Mizuho boosted their price objective on Revance Therapeutics from $26.00 to $30.00 and gave the stock a buy rating in a research note on Friday, September 9th. Finally, Cowen boosted their price objective on Revance Therapeutics from $55.00 to $65.00 in a research note on Thursday, September 8th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average target price of $39.75.

Revance Therapeutics Stock Up 2.6 %

Shares of RVNC opened at $26.61 on Monday. The company has a market cap of $1.95 billion, a PE ratio of -6.91 and a beta of 0.92. The business has a fifty day moving average of $20.04 and a 200 day moving average of $17.32. Revance Therapeutics has a 52-week low of $11.27 and a 52-week high of $30.00. The company has a quick ratio of 3.20, a current ratio of 3.38 and a debt-to-equity ratio of 14.80.

Revance Therapeutics (NASDAQ:RVNCGet Rating) last announced its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.03. Revance Therapeutics had a negative return on equity of 497.77% and a negative net margin of 265.04%. The firm had revenue of $28.37 million for the quarter, compared to analyst estimates of $27.64 million. On average, sell-side analysts expect that Revance Therapeutics will post -3.69 EPS for the current year.

Insider Activity

In other news, SVP Dwight Moxie sold 11,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $27.07, for a total value of $297,770.00. Following the completion of the sale, the senior vice president now directly owns 31,694 shares of the company’s stock, valued at approximately $857,956.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On Revance Therapeutics

Several hedge funds have recently bought and sold shares of RVNC. Federated Hermes Inc. acquired a new position in Revance Therapeutics in the second quarter valued at $1,677,000. ExodusPoint Capital Management LP purchased a new position in Revance Therapeutics in the second quarter valued at about $995,000. Goldman Sachs Group Inc. boosted its holdings in Revance Therapeutics by 26.3% in the second quarter. Goldman Sachs Group Inc. now owns 828,925 shares of the biopharmaceutical company’s stock valued at $11,456,000 after purchasing an additional 172,369 shares during the last quarter. Castleark Management LLC purchased a new position in Revance Therapeutics in the second quarter valued at about $1,787,000. Finally, Corton Capital Inc. purchased a new position in Revance Therapeutics in the second quarter valued at about $162,000. Hedge funds and other institutional investors own 77.08% of the company’s stock.

Revance Therapeutics Company Profile

(Get Rating)

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.

Featured Articles

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.